| Autor: |
Hai-long, Yuan, Ling, Li, Jian-hua, Qu, Bing-zhao, Wen, Ming, Jiang, Jian-ping, Hao, Rong, Chen, Xin-hong, Guo, Yasen, Halida, Shan-zheng, Wang, Ling-lu, Ding |
| Rok vydání: |
2009 |
| Předmět: |
|
| Zdroj: |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 30(2) |
| ISSN: |
0253-2727 |
| Popis: |
To analyze the clinical outcome of human leukocyte antigen (HLA) haploidentical peripheral blood stem cell transplantation (PBSCT) from related donors for hematological malignancies.Thirty-six patients with hematological malignancies, with a median age of 25 (11-48) years, were transplanted with PBSC from an HLA-haploidentical family donors: 7 were 1 locus mismatched and 29 were 2-3 loci mismatched. The recipients received myeloablative conditioning regimen, in combination with different immunosuppressants according to the degree of HLA disparity followed by non-T-cell depleted PBSCT. The median number of CD34+ cells were 11 (4.16-21.00) x 10(6)/kg.All patients achieved sustained, full donor-type engraftment. Fifteen patients (41.7%) developed grade I-II aGVHD. Among 29 patients followed up more than 18 months, 17 (58.6%) developed cGVHD. There was no statistical difference in decrease and recovery of T, B and NK cell subsets after transplantation between HLA haploidentical group and HLA identical PBSCT group. The median follow-up duration was 15 (4 -69) months. Five patients (13.9% ) relapsed. The 2-year probability of leukemia-free survival (LFS) was 82.2%.Non-T-cell depleted HLA-haploidentical PBSCT is safe and feasible for patients with hematological malignancies after myeloablative conditioning regimen combined with intensive immunosuppressants. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
